Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 13, 2011

View Archived Issues

New tumor-homing peptide improves effects of IL-12 gene therapy in vivo

Long-term phase II data presented on eliglustat in type 1 Gaucher's disease

Final data disclosed from randomized menatetrenone trial in hepatocellular carcinoma

Appetite-regulating hormone gene mutation linked to panic disorder

Korean study identifies new risk factors for vascular dementia and Alzheimer's disease

AtheroNova and Maxwell Biotech sign deal for AHRO-001

Researchers at Incyte prepare new tyrosine-protein kinase JAK inhibitors

Novel IL-1 beta inhibitors presented by Ampla Pharmaceuticals

New PI3K-delta inhibitors disclosed by Roche

Genprex provides update on nanomolecular cancer therapy

BMS synthesizes novel inhibitors of DGL-alpha and DGL-beta

Dynavax Technologies receives NIAID grant

InterMune schedules Esbriet launch in Germany

Oncothyreon starts enrollment in phase II PX-866 trial

Novel IAP inhibitors patented by Aegera Therapeutics

Genentech submits NDA for vismodegib

New injectable sustained-release fluocinolone acetonide to enter clinic for posterior uveitis

ImmunoCellular Therapeutics reports updated data from phase I cancer vaccine trial

Moberg Derma completes recruitment in MOB-015 trial

BioSante Pharmaceuticals completes pharmacokinetic study of LibiGel

Abbott commences ABSORB BTK study

Inovio reports interim data from global HIV vaccine study

Studies evaluate GFT-505 in models of NAFLD/NASH

FDA lifts partial clinical hold on trial of NeuVax in breast cancer

Merck & Co. and BGI join to discover and develop biomarkers and genomic technologies

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 4, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...